[Auranofin and aurothiomalate sodium: a comparative review (and II) Efficacy, tolerance and safety].
Batlle Gualda
E
E
D000740:Anemia / Q000139:chemically induced; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001310:Auranofin; D006051:Aurothioglucose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000139:chemically induced; D003875:Drug Eruptions / Q000209:etiology; D004361:Drug Tolerance; D006046:Gold / Q000031:analogs & derivatives*; D006052:Gold Sodium Thiomalate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D010396:Penicillamine / Q000009:adverse effects / Q000627:therapeutic use
D006052:Gold Sodium Thiomalate; D006051:Aurothioglucose; D001310:Auranofin; D006046:Gold; D010396:Penicillamine
Auranofin y aurotiomalato sódico: una revisión comparada (y II). Eficacia, tolerancia y seguridad.